The present invention relates to solid dosage forms of cannabinoid pharmaceutical formulations comprising a solvated cannabinoid for buccal or sublingual administration, and methods of making and using the same. It has been discovered that a solid dosage form for the sublingual/buccal administration of solvated cannabinoids is able to achieve satisfactory or therapeutic plasma levels in a mammalian subject, with fast onset of drug action and improved oral bioavailability compared to the currently marketed cannabinoid products.
